Nick Raich and David Wagner preview Pfizer (PFE) earnings, scheduled for Tuesday premarket. Nick is looking for growth outside of its Covid revenue, and notes the “political risk” it faces under RFK Jr. David thinks it has unrealistic vaccine sales guidance and highlights the failure of its GLP-1 pill, saying he’s on the sidelines for this one.